KTTA — Pasithea Therapeutics Income Statement
0.000.00%
- $6.10m
- -$5.91m
- 18
- 53
- 31
- 26
Annual income statement for Pasithea Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0.015 | 0 | 0 |
Cost of Revenue | ||||
Gross Profit | — | -0.002 | — | — |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 0.041 | 4.52 | 13.6 | 16 |
Operating Profit | -0.041 | -4.51 | -13.6 | -16 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -0.041 | -2.17 | -11.7 | -15.5 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.041 | -2.17 | -11.7 | -15.5 |
Net Income Before Extraordinary Items | ||||
Extraordinary Items | ||||
Net Income | -0.041 | -2.17 | -13.9 | -16 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.041 | -2.17 | -13.9 | -16 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.063 | -1.89 | -8.5 | -12.6 |
Dividends per Share |